Form 4: Alkermes CEO Pops Boosts Stake via RSU Vesting

Alkermes plc CEO Richard F. Pops acquired 149,580 ordinary shares through the vesting of performance-based restricted stock units, while also disposing of 62,230 shares for tax obligations.

Summary

• Richard F. Pops, Director and CEO of Alkermes plc, acquired 149,580 ordinary shares on February 5, 2026.
• This acquisition resulted from the vesting of performance-vesting restricted stock unit awards (2023 PRSUs) granted on February 23, 2023.
• The vesting was contingent on achieving pre-specified performance goals and a relative total shareholder return modifier over a three-year period ending December 31, 2025.
• This represents the final vesting event under the 2023 PRSUs.
• Concurrently, Mr. Pops disposed of 62,230 ordinary shares on February 5, 2026, at a price of $33.55 per share, likely to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Mr. Pops directly beneficially owns 1,377,740 ordinary shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting the achievement of performance targets and an increase in the CEO's direct ownership, albeit with a portion sold for tax.

Positives

• CEO Richard F. Pops acquired a significant number of shares (149,580) through the vesting of performance-based restricted stock units, indicating successful achievement of company performance goals.
• The vesting of the 2023 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a relative total shareholder return modifier, suggesting strong operational and market performance over the three-year period.
• The increase in direct beneficial ownership (net of shares withheld for tax) by the CEO aligns his interests further with shareholders.

Negatives

• A portion of the acquired shares (62,230) was immediately disposed of at $33.55 per share, likely for tax withholding purposes, which is a common practice but reduces the net increase in direct ownership.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the completion of a past performance period for executive compensation.

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions through performance-based awards, can signal management's confidence in the company's long-term strategy and execution. In the biopharmaceutical industry, executive compensation tied to performance metrics is a common practice designed to align leadership incentives with shareholder value creation.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of performance-vesting restricted stock units (PRSUs) with a three-year performance period and a relative total shareholder return modifier is a standard practice in executive compensation across the biopharmaceutical sector. Companies like Pfizer (PFE) and Johnson & Johnson (JNJ) frequently utilize similar long-term incentive plans to motivate executives and link compensation to sustained company performance and market competitiveness.
• The vesting of these awards indicates Alkermes' performance met or exceeded the pre-specified goals, a positive sign consistent with well-managed companies in the industry.

Related Party Transactions

• The transactions involve the CEO of Alkermes plc, Richard F. Pops, acquiring shares through a company-sponsored performance award plan and subsequently disposing of shares to cover tax obligations related to that award.

Stakeholder Impact

• Shareholders: The vesting of performance-based awards suggests the company met its strategic and financial goals, which is generally positive for shareholder value. The CEO's increased direct ownership aligns his interests with shareholders.
• Employees: The successful vesting of executive performance awards can signal a healthy company performance, potentially boosting morale and confidence among employees.
• Management: The CEO's compensation is directly tied to company performance, reinforcing accountability and motivation.

Key Dates

Recommendation

The filing indicates that Alkermes plc achieved its performance goals, leading to the vesting of a significant number of shares for its CEO. This is a positive sign of operational execution and management alignment. However, as a Form 4, it primarily reports on an expected compensation event rather than new strategic developments or financial results. While the achievement of performance targets is good, it's already factored into the company's valuation. The net increase in the CEO's direct ownership is a minor positive, but not enough to warrant a 'buy' recommendation without further fundamental analysis of the company's broader financial health and future prospects. Therefore, a 'hold' recommendation is appropriate, awaiting more comprehensive financial disclosures.

Keywords

Alkermes plc, ALKS, Richard F. Pops, SEC Form 4, Insider Trading, Stock Acquisition, Restricted Stock Units, RSU Vesting, Performance Awards, CEO Stock Ownership, Biopharmaceutical